ASH 2019
Read the full Report (pdf)
American Society of Hematology
7–10 December 2019 Orlando, Florida, USA
Featured articles
CONTENTS
Online First
Late-Breaking Abstracts
Likely new standard of care: Blinatumomab for children with relapsed B-ALL
Pivotal phase 3 trial in cold agglutinin disease: sutimlimab can stop haemolysis
Oral azacitidine improves overall survival in patients with AML in remission
BCL11A as a novel target in gene therapy for sickle cell disease
Adding daratumumab to carfilzomib/dexamethasone prolongs PFS and OS in R/R MM
Long-term data of ropeginterferon alpha-2b in polycythaemia vera
Anti-CD70 is safe with hypomethylating agents in AML
MRD assessment to guide pre-emptive treatment decisions
Luspatercept effective for myelofibrosis-associated anaemia
Arsenic, ATRA, and ascorbic acid in acute promyelocytic leukaemia maintenance
Updated results ECOG-ACRIN E2906: decitabine maintenance after alloSCT
Sickle Cell Disease
Arginine supplements help against sickle cell disease pain
Abatacept prevents graft-versus-host disease in sickle cell patients after alloSCT
Plenary Scientific Session
HOVON-96: Better outcomes with cyclophosphamide after transplantation
Erythroferrone and skeletal changes associated with thalassaemia
Gene editing in congenital neutropenia
Experimental model for limitations of haematopoietic stem cells propagation
Mosunetuzumab: complete remissions in non-Hodgkin lymphoma
Inclusive Medicine
Socioeconomic disparities and survival in paediatric AML
Oral selinexor/pomalidomide/dexamethasone shows activity in heavily pre-treated multiple myeloma
CAR T-cell therapy successful in older non-Hodgkin’s lymphoma patients
Mild renal impairment in African Americans does not affect OS in AML
ALCYONE: New overall survival results for myeloma
Venous Thromboembolism
Rivaroxaban is safe and effective for paediatric venous thromboembolism
Aspirin plus DOAC is not better than a DOAC alone
